Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Incb177054
Cancer
Incyte Corporation
P1/2
CC
(40)
js105
Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.
P1/2
CC
(40)
JS109
Cancer
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.
P1/2
CC
(40)
lcb84
Cancer
LigaChem Biosciences, Inc.
P1/2
CC
(40)
Mage-A1-Specific T Cell Receptor-Transduced Autologous T-Cells
Cancer
T-knife GmbH
P1/2
CC
(40)
mb0151 for
Cancer
Mainline Biosciences (Shanghai) Co., Ltd
P1/2
CC
(40)
mk-1088
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
mk-3120
Cancer
Merck Sharp & Dohme LLC
P1/2
CC
(40)
Monalizumab
Cancer
MedImmune LLC
P1/2
CC
(40)
mrg006a
Cancer
Lepu Biopharma Co., Ltd.
P1/2
CC
(40)
Mrna-4359
Cancer
ModernaTX, Inc.
P1/2
CC
(40)
mt027
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CC
(40)
nts071
Cancer
Nutshell Therapeutics (Shanghai) Co., LTD.
P1/2
CC
(40)
OBI 3424
Cancer
Ascentawits Pharmaceuticals, Ltd
P1/2
CC
(40)
Otp-01
Cancer
Ottimo Pharma Limited
P1/2
CC
(40)
PE0105
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
P1/2
CC
(40)
pe0116
Advanced Solid Tumors
Shanghai YingLi Pharmaceutical Co. Ltd.
P1/2
CC
(40)
Phesgo / / 20,000 Unt In
Advanced Solid Tumors
Hoffmann-La Roche
P1/2
CC
(40)
pm1003
Cancer
Biotheus Inc.
P1/2
CC
(40)
Pyrotinib
Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.
P1/2
CC
(40)
qh101
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CC
(40)
Regn10597
Cancer
Regeneron Pharmaceuticals
P1/2
CC
(40)
Shr-3276
Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1/2
CC
(40)
Shr-4642
Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1/2
CC
(40)
Shr-7787
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(40)
Showing 151 to 175 of 423 assets
Previous
Page 7 of 17
Next
